ATE527350T1 - Verfahren und zusammensetzungen zur behandlung, hemmung und reversierung von bandscheibenerkrankungen - Google Patents

Verfahren und zusammensetzungen zur behandlung, hemmung und reversierung von bandscheibenerkrankungen

Info

Publication number
ATE527350T1
ATE527350T1 AT06733663T AT06733663T ATE527350T1 AT E527350 T1 ATE527350 T1 AT E527350T1 AT 06733663 T AT06733663 T AT 06733663T AT 06733663 T AT06733663 T AT 06733663T AT E527350 T1 ATE527350 T1 AT E527350T1
Authority
AT
Austria
Prior art keywords
compositions
methods
inhibiting
treating
reversing disc
Prior art date
Application number
AT06733663T
Other languages
English (en)
Inventor
Koichi Masuda
Takefumi Gemba
Original Assignee
Univ Rush Medical Center
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rush Medical Center, Anges Mg Inc filed Critical Univ Rush Medical Center
Application granted granted Critical
Publication of ATE527350T1 publication Critical patent/ATE527350T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
AT06733663T 2005-01-11 2006-01-11 Verfahren und zusammensetzungen zur behandlung, hemmung und reversierung von bandscheibenerkrankungen ATE527350T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/033,466 US7585848B2 (en) 2005-01-11 2005-01-11 Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
PCT/US2006/000788 WO2006086105A2 (en) 2005-01-11 2006-01-11 Methods and compositions for treating intervertebral disc disorders

Publications (1)

Publication Number Publication Date
ATE527350T1 true ATE527350T1 (de) 2011-10-15

Family

ID=36653486

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06733663T ATE527350T1 (de) 2005-01-11 2006-01-11 Verfahren und zusammensetzungen zur behandlung, hemmung und reversierung von bandscheibenerkrankungen

Country Status (7)

Country Link
US (1) US7585848B2 (de)
EP (1) EP1841463B1 (de)
JP (2) JP4913072B2 (de)
AT (1) ATE527350T1 (de)
CA (1) CA2594349C (de)
ES (1) ES2374440T3 (de)
WO (1) WO2006086105A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340505A3 (de) * 1993-10-29 2004-07-14 The Brigham And Women's Hospital, Inc. Therapeutische Verwendung von cis-Element-Fallen in vivo
DE60142899D1 (de) * 2000-06-20 2010-10-07 Dainippon Sumitomo Pharma Co Verbindungen für den transfer von oligonukleotiden
EP1407787B1 (de) * 2001-06-20 2009-04-29 Dainippon Sumitomo Pharma Co., Ltd. Verfahren zur förderung des nukleinsäuretransfers
US7378509B2 (en) * 2003-12-02 2008-05-27 Anesiva, Inc. NF-kappaB oligonucleotide decoy molecules
EP1799271A4 (de) * 2004-09-21 2010-05-05 Anesiva Inc Abgabe von polynucleotiden
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US20100196509A1 (en) 2005-02-28 2010-08-05 Jonathan Braun Methods for Diagnosis and Treatment of Endometrial Cancer
WO2006113526A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
US8648052B2 (en) * 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
EP3199635B1 (de) * 2007-05-11 2019-02-06 Adynxx, Inc. Genexpression und schmerzen
US9464135B2 (en) 2007-10-08 2016-10-11 The Regents Of The University Of California Epithelial membrane protein-2 (EMP2) and proliferative vitroretinopathy (PVR)
WO2010079811A1 (ja) * 2009-01-07 2010-07-15 学校法人久留米大学 椎間板変性関連疾患感受性遺伝子およびその用途
EP2846839B1 (de) 2012-05-10 2019-02-20 Adynxx, Inc. Formulierungen zur abgabe von wirkstoffen
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
CN105255862B (zh) * 2014-12-30 2018-05-22 南京艾德凯腾生物医药有限责任公司 一种用于制备抑制肿瘤生长药物的寡聚核酸及其应用
SE1550338A1 (en) * 2015-03-20 2016-09-21 Stayble Therapeutics Ab A composition for use in the treatment of intervertebral misalignment
US20200017853A1 (en) * 2016-02-29 2020-01-16 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression
CN113453695A (zh) * 2018-12-24 2021-09-28 加州大学评议会 用嵌合体诱饵治疗脊柱病症
CN110585423A (zh) * 2019-10-24 2019-12-20 内蒙古医科大学第二附属医院 Il-6在制备治疗腰椎间盘突出药物中的应用
CN110613837A (zh) * 2019-10-24 2019-12-27 内蒙古医科大学第二附属医院 TGF-β在制备预防或治疗腰椎间盘突出药物中的应用
US20230069350A1 (en) * 2020-01-15 2023-03-02 The Regents Of The University Of California Methods and compositions relating to prolonged inflammatory inhibition and/or prolonged treatment of spinal pain by chimera decoy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
EP0584238A1 (de) 1991-05-17 1994-03-02 Chiron Corporation Inhibitor von nf-kb transkriptions-aktivator und seine verwendungen
CA2105595A1 (en) 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
CA2131587A1 (en) 1993-09-07 1995-03-08 Yinon Ben-Neriah Method for regulation of nf-kb
EP0652290A1 (de) 1993-09-07 1995-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methode zur Regulierung von NF-kappa B
EP1340505A3 (de) 1993-10-29 2004-07-14 The Brigham And Women's Hospital, Inc. Therapeutische Verwendung von cis-Element-Fallen in vivo
US6399376B1 (en) 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
EP0824918B1 (de) 1995-05-12 2007-03-28 AnGes MG, Inc. HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
US20010006948A1 (en) * 1998-11-25 2001-07-05 James D. Kang Gene transfer to intervertebral disc cells
US20030113796A1 (en) * 2000-01-27 2003-06-19 Sims John E. FIL-1 theta DNAs and polypeptides
DE60231063D1 (de) * 2002-02-01 2009-03-19 Anges Mg Inc N zur behandlung von aneurysmen
JPWO2003099339A1 (ja) * 2002-05-29 2005-09-22 アンジェスＭｇ株式会社 炎症性疾患を処置および予防するためのデコイ組成物
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc

Also Published As

Publication number Publication date
CA2594349C (en) 2012-05-29
JP4913072B2 (ja) 2012-04-11
ES2374440T3 (es) 2012-02-16
US7585848B2 (en) 2009-09-08
US20060153847A1 (en) 2006-07-13
JP2008526968A (ja) 2008-07-24
EP1841463A4 (de) 2008-08-27
EP1841463B1 (de) 2011-10-05
JP2012092104A (ja) 2012-05-17
EP1841463A2 (de) 2007-10-10
WO2006086105A3 (en) 2007-10-25
CA2594349A1 (en) 2006-08-17
WO2006086105A2 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
ATE527350T1 (de) Verfahren und zusammensetzungen zur behandlung, hemmung und reversierung von bandscheibenerkrankungen
NL301145I2 (nl) Tirbanibulin
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
WO2005117846A3 (en) Ice inhibitors for the treatment of autoinflammatory diseases
NO20061197L (no) Proteasominhibitorer og fremgangsmater for anvendelse av samme
DK1846424T3 (da) Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
WO2006105304A3 (en) Phenyl and pyridyl lta4h modulators
EA200900571A1 (ru) Композиции chk1 ингибиторов
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
BRPI0607985A2 (pt) modulador da dscr1, métodos de tratamento, método de melhoria de efeitos colaterais e método de inibição do crescimento de tumores
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
EA200970164A1 (ru) Ингибиторы каспазы на основе пиридазинонового каркаса
RS54185B1 (en) USE OF 24-ORDER
TW200716561A (en) P38 inhibitors and methods of use thereof
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
DE60327793D1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
ATE438403T1 (de) Verwendung eines pde5-hemmers zur behandlung und vorbeugung von hypopigmentierungsstörungen
ATE497767T1 (de) Verfahren zur behandlung von entzündungserkrankungen
DK1768948T3 (da) Substituerede aminoforbindelser som hæmmere af optag af 5-HT/NA

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties